XAXavier Alsina-Restoy

Xavier Alsina-Restoy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xavier Alsina-Restoy has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Checkpoint Inhibitor Pneumonitis: Key Insights for Pulmonologists

    by Candela Serra, Mariana Benegas, Xavier Alsina-Restoy, Nuria Roger-Casals, Fernanda Hernández-González

    Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, offering significant efficacy and a generally favorable safety profile. However, they are associated with a spectrum of immune-related adverse events (irAEs), among which pneumonitis stands out due to its relatively high mortality. This condition is characterized by nonspecific clinical manifestations and a broad differential diagnosis, often requiring the involvement of pulmonologists for accurate diagnosis and management. Given its potential severity, it is crucial for pulmonologists to be well-versed in recognizing and addressing checkpoint inhibitor pneumonitis (CIP). In this narrative review, we examine reported cases of pneumonitis in patients with various types of cancer treated with ICIs. The article explores the mechanisms of action of ICIs, the underlying pathophysiology of pneumonitis, associated risk factors, clinical presentation, diagnostic approaches, and current treatment strategies, intended to support pulmonologists in improving early detection and implementing evidence-based management of this potentially life-threatening complication.


  • Open Access

    Evolving Concepts in Progressive Pulmonary Fibrosis: A Clinical Update

    by María Belén Noboa-Sevilla, Fernanda Hernández-González, Sandra Cuerpo-Cardeñosa, Xavier Alsina-Restoy, Nancy Pérez-Rodas, Alejandro Frino-García, Miguel Alonso-Villares, Elvis Matheus-Ramírez, Jacobo Sellarés

    Progressive pulmonary fibrosis (PPF) is a clinical syndrome associated with worsening quality of life and increased mortality among patients with various interstitial lung diseases. This review aims to update the concepts and criteria that adequately define PPF, aiming to facilitate earlier recognition and optimize clinical management. Fibrosing interstitial lung disease (ILD-f) can progress over time despite optimal management of the underlying conditions. Current criteria for defining PPF include worsening respiratory symptoms, decline in pulmonary function tests (particularly forced vital capacity and diffusing capacity), and radiographic progression over a 1-year follow-up period. However, implementation of these criteria in clinical practice poses challenges. This review discusses the limitations of current evaluation methods and proposes future directions, including the need for validated symptom assessment tools, standardization of pulmonary function testing, and improvements in quantitative radiological evaluation methods.

  • Six‐minute walking distance and desaturation–distance ratio in allogeneic stem cell transplantation

    by Yolanda Torralba‐García, Xavier Alsina‐Restoy, Rodrigo Torres‐Castro, Elena Gimeno‐Santos, Noemi de Llobet‐Viladons, Montserrat Rovira‐Tarrats, Nuria Borràs‐Maixenchs, Montserrat Valverde‐Bosch, Carles Agustí García‐Navarro, Jordi Vilaró, et al.

    Background: Most patients with haematological malignancies who undergo allogeneic haematopoietic stem cell transplant (HSCT) receive chemotherapy before the transplant to control the disease. Certain chemotherapy drugs can cause lung toxicity. Conversely, in patients with chronic respiratory conditions, the 6‐min walking test (6MWT) and the desaturation–distance ratio (DDR) have demonstrated prognostic significance. Our objective was to determine whether the 6MWD and DDR, assessed prior to HSCT, have a prognostic impact on survival at 24 months post‐HSCT.Methods: A prospective experimental study was conducted in consecutive patients referred for allogeneic HSCT at Hospital Clinic, Barcelona, Spain. A complete functional respiratory study, including the 6MWT and DDR, was conducted prior to admission. The area under the curve (AUC) and cut‐off points were calculated. Data on patients' characteristics, HSCT details, main events, with a focus on lung complications, and survival at 24 months were analysed.Results: One hundred and seventy‐five patients (39% women) with mean age of 48 ± 13 years old were included. Before HSCT, forced vital capacity and forced expiratory volume in the first second were 96% ± 13% predicted and 92% ± 14% predicted, respectively; corrected diffusing capacity for carbon monoxide 79% ± 15% predicted; 6MWD was 568 ± 83 m and DDR of .27 (.20–.41). The cut‐off points for 6MWD and DDR were 566 m, [.58 95% CI (.51–.64)], p = .024 and .306, [.63 95% CI (.55–.70)], p = .0005, respectively. The survival rate at 24 months was 55%.Conclusion: Our results showed that individuals who exhibit a 6MWD shorter than 566 ms or a decline in DDR beyond .306 experienced reduced survival rates at 24 months after HSCT.


  • Open Access

    Blood Immunophenotypes of Idiopathic Pulmonary Fibrosis: Relationship with Disease Severity and Progression

    by Nuria Mendoza, Sandra Casas-Recasens, Núria Olvera, Fernanda Hernandez-Gonzalez, Tamara Cruz, Núria Albacar, Xavier Alsina-Restoy, Alejandro Frino-Garcia, Gemma López-Saiz, Lucas Robres, et al.

    (1) The role of the immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF) remains controversial. We hypothesized that peripheral blood immune phenotypes will be different in IPF patients and may relate to the disease severity and progression. (2) Whole blood flow cytometry staining was performed at diagnosis in 32 IPF patients, and in 32 age- and smoking-matched healthy controls. Thirty-one IPF patients were followed up for one year and categorized as stable or progressors based on lung function, deterioration and/or death. At 18–60 months, immunophenotypes were characterized again. (3) The main results showed that: (1) compared to matched controls, at diagnosis, patients with IPF showed more neutrophils, CD8+HLA-DR+ and CD8+CD28− T cells, and fewer B lymphocytes and naïve T cells; (2) in IPF, circulating neutrophils, eosinophils and naïve T cells were associated with lung function abnormalities; (3) patients whose disease progressed during the 12 months of follow-up showed evidence of cytotoxic dysregulation, with increased CD8+CD28− T cells, decreased naïve T cells and an inverted CD4/CD8 ratio at baseline; and (4) blood cell alterations were stable over time in survivors. (4) IPF is associated with abnormalities in circulating immune cells, particularly in the cytotoxic cell domain. Patients with progressive IPF, despite antifibrotic therapy, present an over-activated and exhausted immunophenotype at diagnosis, which is maintained over time.


  • Analysis of the Activity of a High Complexity Unit in Smoking Treatment: Results and Role of Comorbidity

    by A.D. Frino-Garcia, M. Graell Gabriel, M. Andreu Mondon, X. Alsina-Restoy, N. Pérez-Rodas, M.B. Noboa-Sevilla, F. Hernandez-Gonzalez, S. Mondon-Vehils, J. Sellares Torres

  • Open Access

    Pulmonary Rehabilitation in Sarcoidosis: A Systematic Review and Meta-analysis

    by J. Sellares Torres, X. Alsina-Restoy, R. Torres-Castro, C. Estrella, E. Gimeno-Santos, L. Solis-Navarro, J.R. Francesqui Candela, F. Hernandez-Gonzalez, M. Ramos-Casals, I. Blanco

  • Reference Equation ​​for the Six-minute Walk Test in the Ecuadorian Population

    by M.B. Noboa-Sevilla, W.D. Arias, R. Torres-Castro, G. Cruz-Murillo, H. Guaman-Arcos, N. Perez-Rodas, A.D. Frino-Garcia, F. Hernandez-Gonzalez, X. Alsina-Restoy, J. Sellares Torres

  • Open Access

    Assessment of Exercise Capacity in Post-COVID-19 Patients: How Is the Appropriate Test Chosen?

    by Rodrigo Torres-Castro, Rodrigo Núñez-Cortés, Santiago Larrateguy, Xavier Alsina-Restoy, Joan Albert Barberà, Elena Gimeno-Santos, Agustin Roberto García, Oriol Sibila, Isabel Blanco

    There is a wide range of sequelae affecting COVID-19 survivors, including impaired physical capacity. These sequelae can affect the quality of life and return to work of the active population. Therefore, one of the pillars of following-up is the evaluation of physical capacity, which can be assessed with field tests (such as the six-minute walk test, the one-minute standing test, the Chester step test, and the shuttle walking test) or laboratory tests (such as the cardiopulmonary exercise test). These tests can be performed in different contexts and have amply demonstrated their usefulness in the assessment of physical capacity both in post-COVID-19 patients and in other chronic respiratory, metabolic, cardiologic, or neurologic diseases. However, when traditional tests cannot be performed, physical function can be a good substitute, especially for assessing the effects of an intervention. For example, the Short Physical Performance Battery assessment and the Timed Up and Go assessment are widely accepted in older adults. Thus, the test should be chosen according to the characteristics of each subject.


  • Does arterial oxygenation during exercise add prognostic value in pulmonary arterial hypertension?

    by Xavier Alsina-Restoy, Rodrigo Torres-Castro, Yolanda Torralba-García, Felip Burgos, Joan Albert Barberà, Àlvar Agustí, Isabel Blanco


  • Effects of pulmonary rehabilitation on patients with sarcoidosis: a systematic review and meta-analysis of randomised controlled trials

    by Xavier Alsina-Restoy, Hospital Clínic de Barcelona, Rodrigo Torres-Castro, Estrella Caballeria, Lilian Solis-Navarro, Joel Francesqui, Elena Gimeno-Santos, Fernanda Hernández, Isabel Blanco, Jacobo Sellarés

    Review question / Objective: Is pulmonary rehabilitation an effective intervention in patients with sarcoidosis? Condition being studied: Sarcoidosis. Eligibility criteria: We will include studies published until March 2022. The population studied must be adults (>18y) with diagnosis of sarcoidosis that performed a structured program of pulmonary rehabilitation. We will include only outpatients. They must be patients with stable disease and without exacerbation for at least one month.